Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
LIGHTHOUSE Study Group, Devaki Shilpa Surasi, Matthias Eiber, Tobias Maurer, Mark A. Preston, Brian T. Helfand, David Josephson, Ashutosh K. Tewari, Diederik M. Somford, Soroush Rais-Bahrami, Bridget F. Koontz, Peter J. Bostrom, Albert Chau, Phillip Davis, David M. Schuster, Brian F. Chapin, Mohamad Allaf, Gerald Andriole, Ryan J. Avery, Norbert AvrilHelen Barker, Laurence Belkoff, Lars Budäus, Michael L. Cher, Diane Chisholm, Matthew F. Covington, Ian Cox, Michael Ferrandino, Mark T. Fleming, Dinko Franceschi, Peter Gardiner, Benjamin Gartrell, David Gauden, Ergela Hasa, Rick Hermsen, Thomas Horn, Pooya Iranpour, Heather Jacene, Isuru Jayaratna, Shreyas S. Joshi, Matthew Kay, Lale Kostakoglu, Phillip Kuo, William Lavely, Mary Lokuta, Benjamin Lowentritt, Matthew P. Miller, Jeffrey W. Nix, Kenneth Ogan, Ross Penny, Morand Piert, Andrei Purysko, Gregory Ravizzini, Daniel Saltzstein, Bital Savir-Baruch, Barry A. Siegel, Thomas Steuber, Przemyslaw Twardowski, Edward Uchio, Gary A. Ulaner, Jenna M. Wixom, Don Yoo, Katherine Zukotynski
Dive into the research topics of 'Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)'. Together they form a unique fingerprint.